Kalohexis Welcomes Thomas Forest Farb-Horch to Board, Driving Innovation in Metabolic Disease Care

Kalohexis Appoints Thomas Forest Farb-Horch to Board of Directors

Kalohexis, Inc., a biotechnology company in the clinical stage, recently announced the significant appointment of Thomas Forest Farb-Horch to their Board of Directors. This decision aims to bolster the company’s efforts in advancing metabolic disease treatments, specifically for conditions such as obesity and cancer cachexia, by utilizing the melanocortin system.

Mr. Farb-Horch is a seasoned entrepreneur and executive with extensive experience in the life sciences sector. His considerable expertise spans company building, capital markets, data science, and artificial intelligence (AI), making him a valuable addition to Kalohexis as it navigates its next growth phase. According to Russell Potterfield, the Chief Executive Officer of Kalohexis, Farb-Horch's combination of leadership and governance experience in the life sciences and technology sectors makes him particularly well-suited to guide the company’s advancements in clinical programs.

Experience and Contributions

Farb-Horch brings over 30 years of experience in founding and leading life sciences and technology firms. His previous roles include pivotal positions at publicly traded companies, such as President and Chief Operating Officer of Indevus Pharmaceuticals, which underwent acquisition by Endo Pharmaceuticals. His track record at Interneuron Pharmaceuticals and Cytyc Corporation further highlights his leadership capabilities, where he played a crucial role during formative years that predated significant financial transactions.

Currently, Farb-Horch serves as the Chief Executive Officer and Director of Thrive Bioscience—an organization that specializes in providing computational and data infrastructure for AI-driven drug discovery within life sciences. His previous successes include contributions to notable companies such as HNC Software, Exact Sciences, and Retek—many of which achieved remarkable growth and successful acquisitions.

Kalohexis's Clinical Focus

Farb-Horch expressed enthusiasm about the opportunity presented by Kalohexis to tackle critical issues in metabolic diseases. The ongoing pursuit of innovative approaches in treating obesity and cancer cachexia through the melanocortin system is a compelling prospect—one that Farb-Horch is keen to explore further.

Kalohexis focuses on the body's natural regulation of metabolic homeostasis and has been working on therapeutic peptide candidates designed to affect the central MC3R and MC4R receptors. One of its lead pipeline programs, 710GO, is an oral agonist aimed at promoting healthier and sustainable weight loss among those facing general obesity.

Additionally, the company is developing mifomelatide, aimed at mitigating cachexia in patients with advanced cancer, showcasing their intent to address a significant gap in metabolic disorder treatments.

Looking Ahead

As Kalohexis moves forward, the integration of advanced data science and AI tools, alongside Farb-Horch’s extensive experience, is expected to play a pivotal role in shaping its future clinical strategies and organizational growth. Farb-Horch's contributions will undoubtedly prove essential as Kalohexis continues to innovate and expand its clinical pipeline.

For more information about Kalohexis and its pioneering approaches to metabolic disease care, visit Kalohexis or follow the company on LinkedIn and X.